MindX Sciences

MindX Sciences, founded in 2019 and based in Cambridge, USA, is pioneering a data-driven, biomarker-based platform for precision mental health. The company's core offering appears to be the MindX One™ blood test, a liquid biopsy designed for the objective assessment of conditions like stress, pain, and memory impairment, with the goal of guiding personalized treatment. Recent achievements include winning the Mayo ASU Healthcare Accelerator competition in 2026 and securing key patent allowances, indicating a focus on commercializing its diagnostic technology and building partnerships.

Blood-based liquid biopsy platform measuring RNA biomarkers for objective assessment, risk prediction, treatment matching, and monitoring in mental health and pain conditions.

MindX operates in the emerging precision psychiatry diagnostics space. Potential competitors include large clinical lab companies developing CNS panels, digital mental health apps incorporating biomarker tracking, and academic spin-offs. Its key differentiator is a broad, patented portfolio focused specifically on blood-based RNA biomarkers for multiple psychiatric and pain conditions.